News | Wearables | February 23, 2021

RhythMedix Launches Next-Generation RhythmStar Wearable Cardiac Monitor With Built-In Cellular Connectivity

Technology designed to improve cardiac monitoring for faster arrhythmia detection

Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar wearable device with built-in 4G cellular connectivity. The cardiac telemetry monitor can be worn for extended remote monitoring without the need for an additional phone or communication device. 

Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar wearable device with built-in 4G cellular connectivity. The cardiac telemetry monitor can be worn for extended remote monitoring without the need for an additional phone or communication device. 


February 23, 2021 — Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar wearable device with built-in 4G cellular connectivity. The novel cardiac telemetry monitor is discreetly worn for extended remote monitoring without the need for an additional phone or communication device. 

The technology enables rapid ECG analysis and reporting of cardiac abnormalities by RhythMedix's team of U.S.-based certified technicians, who alert physicians if an arrhythmia of concern is detected. RhythmStar is now available with HeartTime™ on-demand telemetry mode, an innovative platform that allows physicians to evaluate cardiac activity and expedite care via a telemedicine appointment, limiting the need for an in-person office visit.

Heart arrhythmias are a major health concern that doubles the risk of death in an estimated 33.5 million people worldwide.[1,2] While remote cardiac monitoring has improved arrhythmia detection, patient compliance and timely access to heart activity currently limit accurate and timely diagnosis.

"The novel wearable RhythmStar monitoring device offers increased patient compliance and allows for accurate assessment of cardiac rhythm in real time," said Steven DaTorre, M.D., FACC, a clinical cardiologist at Cooper University Health Care in New Jersey. "It also allows me to remain connected to my patients throughout their monitoring period, which may expedite a life-saving diagnosis."  

The sleek, one-piece device, with built-in 4G cellular technology, is the first wearable multi-modality cardiac monitor (Holter, event and MCT) that connects patients and clinicians for improved patient care. RhythmStar integrates seamlessly into clinical practice, helping physicians make informed treatment decisions that allow patients to enjoy life, without missing a beat.

"We are excited to offer physicians and their patients our unique monitoring solution that improves patient compliance, helps accelerate diagnosis, and allows physicians to stay virtually connected to their patients with on-demand access to clinical data", stated Brian Pike, president, chief operations officer and co-founder of RhythMedix. "We look forward to bringing this next-generation RhythmStar technology to physicians across the U.S. in 2021."

For more information: www.rhythmedix.com

 

References:

1. W.B Kannel, P.A Wolf, E.J Benjamin, D Levy. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 1. The American Journal of Cardiology. DOI: https://doi.org/10.1016/S0002-9149(98)00583-9.

2. Sumeet S. Chugh, Rasmus Havmoeller, Kumar Narayanan, et al. Worldwide Epidemiology of Atrial Fibrillation. A Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847. Originally published 17 Dec 2013. https://doi.org/10.1161/CIRCULATIONAHA.113.005119.
 

Related Content

Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

Home October 29, 2021
Home
News | Cardiac Diagnostics

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

Home October 04, 2021
Home
News | Cardiac Diagnostics

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

Home September 28, 2021
Home
News | Cardiac Diagnostics

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation ...

Home July 29, 2021
Home
News | Cardiac Diagnostics

July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation ...

Home July 01, 2021
Home
News | Cardiac Diagnostics

March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potential ...

Home March 08, 2021
Home
News | Cardiac Diagnostics

March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management ...

Home March 03, 2021
Home
Subscribe Now